A phase I study of Dz13 drug targeting the c-Jun gene in subjects with melanoma skin cancer

Phase 1

Withdrawn

• Conditions: in-transit or satellite melanoma; Cancer - Malignant melanoma

• Registration Number: ACTRN12613000302752
• Lead Sponsor: The University of New South Wales

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

Diagnosed dermal in-transit or satellite metastatic melanoma with at least 3 measurable lesions at minimum distance of 5 cm from each other
ECOG performance status 0-1
Acceptable haematologic, coagulation, renal and hepatic function

Exclusion Criteria

Metastatic/in-transit or satellite lesions located on face, head and neck
Women of child bearing age
Prior or co-existing malignancy
Radiotherapy to >30% bone marrow in previous 3 months
Clinically significant non-malignant disease
Current immunosuppression
History of immune-mediated throbocytopenia or other platelet disease
Enrolment in another clinical study involving any other investigational agent

Study & Design

• Study Type: Interventional
• Study Design: Not specified